Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Patent issued to the former HMR for new series of bone resorption inhibitors

Feb. 28, 2000

Extended-release metformin shows good phase I results

Feb. 28, 2000

Ligand presents data on novel rexinoid with potential in diabetes and obesity therapy

Feb. 28, 2000

Buccal insulin/metformin combination therapy tested in type II diabetes

Feb. 25, 2000

Magainin to begin clinical program for squalamine in genetic bone disorder

Feb. 25, 2000

Salk team identifies potential target for the elusive male contraceptive

Feb. 24, 2000

Compounds activating PPAR isoforms described by Merck for lipid disorders, diabetes

Feb. 24, 2000

New emergency contraceptive option available for U.K. women

Feb. 22, 2000

Potent EP1 receptor ligands in early development at Ono

Feb. 22, 2000

Polyhydroxyalkylpyrazine derivatives for diabetes synthesized at Aventis

Feb. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...